Hypertension, Portal Clinical Trial
Official title:
MR-based Models for Noninvasive Detection of Clinically Significant Portal Hypertension in Cirrhosis (CHESS1802)
Clinically significant portal hypertension (CSPH) is associated with an incremental risk of
esophageal varices and overt clinical decompensations in cirrhosis. However, hepatic venous
pressure gradient (HVPG) measurement, the gold standard for defining CSPH (HVPG≥ 10mmHg) is
invasive and therefore not suitable for routine clinical practice.
This is a multi-center diagnostic trial conducted at high-volume liver centres designed to
determine the accuracy of MR-based models (investigational technology) for noninvasive
detection of a CSPH in patients with cirrhosis. Transjugular HVPG measurement by means of
catheterization of a hepatic vein with a balloon catheter is the gold-standard method to
assess the presence of CSPH.
Clinically significant portal hypertension (CSPH) is associated with an incremental risk of
esophageal varices and overt clinical decompensations in cirrhosis. However, hepatic venous
pressure gradient (HVPG) measurement, the gold standard for defining CSPH (HVPG≥ 10mmHg) is
invasive and therefore not suitable for routine clinical practice.
This is a multi-center diagnostic trial conducted at high-volume liver centres (Zhongda
Hospital, Medical School of Southeast University; Affiliated Lishui Hospital of Zhejiang
University; Shandong Provincial Hospital affiliated to Shandong University; Beijing 302
Hospital; Xingtai People's Hospital; Shunde Hospital, Southern Medical University; The First
Hospital of Zhengzhou University; Shanghai Public Health Clinical Center, Fudan University;
The First Hospital of Lanzhou University; Nanfang Hospital of Southern Medical University;
Ankara University School of Medicine) designed to determine the accuracy of MR-based models
(investigational technology) for noninvasive detection of a CSPH in patients with cirrhosis.
Transjugular HVPG measurement by means of catheterization of a hepatic vein with a balloon
catheter is the gold-standard method to assess the presence of CSPH.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03713606 -
Serum Biomarkers for Portal Hypertension in Cirrhosis (Pan-CHESS1802)
|
||
| Recruiting |
NCT02504034 -
Interventional Radiology for the Treatment of Symptomatic Portal Hypertension in Patients With Cavernous Transformation of Portal Vein
|
N/A | |
| Recruiting |
NCT02505152 -
Percutaneous Transhepatic Intrahepatic Portosystemic Shunt for Treatment of Portal Vein Occlusion With Symptomatic Portal Hypertension After Splenectomy
|
N/A | |
| Completed |
NCT02669875 -
Serelaxin To Lower Portal Pressure
|
Phase 2 | |
| Recruiting |
NCT04720456 -
SHAPE of Portal Hypertension in Children
|
Phase 2 | |
| Completed |
NCT04645550 -
Apixaban, Warfarin and Aspirin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy（ESAWAAPT）
|
Phase 4 | |
| Recruiting |
NCT02305914 -
Follow-up Study of Complications of Acute Pancreatitis
|
N/A | |
| Completed |
NCT01095185 -
Efficacy of Statin Association With Standard Treatment in Prevention of Recurrent Hemorrhage in Patient With Cirrhosis and Variceal Bleeding
|
Phase 3 | |
| Terminated |
NCT05282121 -
A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)
|
Phase 2 | |
| Completed |
NCT00004641 -
A Study to Prevent Complications of High Blood Pressure Caused by Hepatitis in Patients With Cirrhosis
|
Phase 2 | |
| Completed |
NCT03138915 -
Radiomics Signature of Hepatic Venous Pressure Gradient (rHVPG) With CT Angiography (CHESS1701)
|
N/A | |
| Completed |
NCT03175731 -
PPIs and Gastroesophageal Varices in Liver Cirrhosis (PPIs: Proton Pump Inhibitors)
|
Phase 4 | |
| Active, not recruiting |
NCT04315571 -
Comparing Ascites Relief In Two Standard Treatments: Large Volume Paracentesis Vs. Early Tips Using Viatorr Controlled Expansion Stents
|
N/A | |
| Completed |
NCT03459378 -
Outcome After TIPS
|
||
| Recruiting |
NCT03470389 -
Establishment and Assessment of the HVPG Using Biofluid Mechanics (HVPGBFM)
|
N/A | |
| Completed |
NCT02462967 -
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
|
Phase 2 | |
| Active, not recruiting |
NCT01097811 -
Comparison Between Erythromycin and Neomycin Treatment of Hepatic Encephalopathy
|
N/A | |
| Terminated |
NCT06082843 -
A Study to Test Whether Avenciguat Helps People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) Who Had Bleeding in the Esophagus or Fluid Accumulation in the Belly
|
Phase 2 | |
| Recruiting |
NCT03315767 -
Spleen-ARFI-assisted-Portal-Hypertension-Evaluation-Study (SAPHES)
|
N/A | |
| Terminated |
NCT05161481 -
A Study to Test Whether Two Different Doses of Avenciguat Help People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Live
|
Phase 2 |